Latest news

Preclinical Mouse Tumor Models Of Immune Checkpoint Inhibition

01 / 28 / 2016

To test novel combination therapies aiming at increasing responses rates to immune checkpoint inhibitors, Explicyte has optimized a range of syngeneic mouse tumor models treated with anti-CTLA-4 or anti-PD-1/PD-L1 monoclonal antibodies. Starting with basic measurements of in vivo efficacy, our in vivo services extends to comprehensive biomarker studies, to determine the in vivo mechanism of action of novel treatments.


Syngeneic Mouse Model Of Glioblastoma

01 / 22 / 2016

Syngeneic Mouse Model Of Glioblastoma

To assess the in vivo efficacy and mechanism of action of novel therapeutic strategies for brain cancer, Explicyte has validated a syngeneic mouse tumor model of glioma, which closely mimics human glioblastoma (GBM) in terms of tumor progression and immune response. A key advantage of this model, based on the GL261-Luc2 murine glioma cell line, relies on the possibility of quantifying tumor growth in live animals by bioluminescence imaging along the study.

IDO1 Expression Does Not Strictly Match L-Kynurenine Production In Cancer Tissue

04 / 21 / 2015

This PLOS ONE paper, co-authored by Alban Bessède, CSO of Explicyte, demonstrates that the expression of tryptophan-degrading enzyme IDO1 is not strictly associated with L-Kynurenine production in breast and colorectal cancer tissues. The study suggests that the in situ detection of L-Kynurenine could serve to stratify patients in the context of cancer immunotherapies targeting tryptophan catabolic enzymes: indoleamine 2,3-dioxygenase (IDO-1/-2) or tryptophan 2,3-dioxygenase 2 (TDO2).